Search

The article reports on the judgment delivered by the European Court of Justice on May 4, 2006 regarding applications for Special Protection Certificates (SPC) and their scope. The case was focused on the combination therapy in the form on an implant developed by Massachusetts Institute of Technology for treating brain tumors.

The article reflects on the positive opinion of the European Medicines Agency (EMEA) for generic biosimilar drugs since its issuance of regulatory guidelines and some related cases regarding these generic drugs. It also discussed the planned entry of biosimilar drugs into the United States. The US Food and Drug Administration (FDA) has yet to decide on the issue. Other related reports were also discussed.

The article tackles three court cases concerning pharmaceutical companies in Great Britain. The first case involves Synthon BV and Smithkline Beecham PLC. The second case involves Ranbaxy UK Ltd and Warner Lambert while the third is a case between Mayne Pharma and Teva UK. The author further discusses important details and information regarding the cases.